Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on AIM ImmunoTech — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plans Book a 15-min walkthrough

▶

Watch the 2-minute tour · with sound

AIM ImmunoTech Announces $1.26 Million Registered Direct Offering

Sep 30, 2024•over 1 year ago

Contract Type

partnership

OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Description

AIM ImmunoTech Inc. has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0.27 per share. The gross proceeds to the Company from the offering are estimated to be approximately $1.26 million.

Company Information

Company

AIM ImmunoTech

Location

Ocala, Florida, United States

About

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

Predictive Intelligence

Strategic

ML-powered predictions for AIM ImmunoTech's next move

Learn about Strategic plan

Related People

Suggested for you

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months